Form EFFECT NeuroSense Therapeutics
Tweet
Share
E-mail| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | April 8, 2024 |
| Accession Number: | 0001213900-24-030479 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NeuroSense ALS drug meets Phase 2b primary endpoint in TDP-43 trial
- ELEKTROS Advances Its Long-Term Strategy to Help Shape the Future of High-Speed Electric Vehicle Charging
- As Global Markets Reach New Heights, ELEKTROS Strengthens Its Vision for the Next Generation of High-Speed EV Charging Infrastructure
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
